DOSES STUDIED
Ipamorelin Dosage, As It Appears in the Research Record
The doses and routes that show up in the published studies — described third-person, with the kinetics that make timing the central question. No human dosing guidance.
Read this first
This page describes what doses of ipamorelin researchers gave, to which species, by which route — and nothing more. It is not a how-to and contains no recommended human dose. That boundary matters here because ipamorelin is not an approved medicine and the only completed human trial used it by vein in a hospital, twice daily, for up to a week [2]. The thread that ties the doses together is pharmacokinetics: ipamorelin's level falls by half about every two hours and the growth-hormone pulse it triggers peaks near 40 minutes, so when a dose is given matters more than holding a steady blood level [1]. Below are the study doses, the routes that have been tested, what the half-life implies for timing, and a plain note on the cjc-1295 ipamorelin question — always as research context, never as instruction.
Doses that appear in the studies
In the human PK/PD study, healthy volunteers received single IV doses of 4.21, 14.02, 42.13, 84.27, and 140.45 nmol/kg over 15 minutes [1]. The Phase 2 ileus trial used 0.03 mg/kg IV twice daily for up to 7 days [2]. Rodent work spans a wide range: rat bone-growth studies used 18, 90, and 450 microg/day subcutaneously, divided three times daily over 15 days [4]; the 2024 ferret cachexia study used 1–3 mg/kg intraperitoneally [5]. These are species- and model-specific experimental doses — they do not convert to a human protocol, and none is presented here as one.
Routes that have been studied
Intravenous administration carries the human PK and clinical-trial data and much of the rodent efficacy work [1][2]. Subcutaneous injection dominates the rodent bone and body-composition studies — and is also the dominant route in off-label community use, though that use has no published human PK or safety characterization [4]. Intraperitoneal dosing appears in rodent and ferret efficacy studies [5]. Oral administration is effectively a dead end for ipamorelin itself: it is not orally bioavailable, and oral activity belongs only to engineered analogs such as NN703 (~30% in dogs) built specifically to overcome that [10][11].
What the half-life implies for timing
Ipamorelin's terminal half-life is about 2 hours in humans, with clearance 0.078 L/h/kg and steady-state volume of distribution 0.22 L/kg [1]. The GH pulse it triggers peaks near 40 minutes and then subsides as a single discrete event [1]. The practical consequence in the research literature is that ipamorelin is studied as a pulse generator, not a continuous-level drug — its short residence means each dose produces a brief, self-limiting GH burst rather than a sustained elevation. Full detail of the elimination time-course is on the how long does ipamorelin stay in your system page.
How to reconstitute cjc-1295 ipamorelin 5mg
In the research-supply literature, ipamorelin is handled as a lyophilized (freeze-dried) powder — free base or acetate salt — reconstituted with bacteriostatic water before use. As a peptide it degrades with heat and repeated freeze-thaw, so reconstituted solution is typically refrigerated. These are general peptide-handling observations from the research-supply context, not a clinical preparation instruction and not a protocol — this site provides no reconstitution recipe, dose, or volume for human use, and the only documented human administration of ipamorelin was intravenous and clinician-supervised [2].
How much cjc-1295 ipamorelin should i take
This digest gives no answer to how much cjc-1295 ipamorelin a person should take, because no controlled human trial of the combination establishes any dose for any outcome [2]. The community 'stack' protocols that pair the two subcutaneously have no peer-reviewed human dosing basis and are described in the literature as anecdotal, not recommended [2]. What the evidence does support is mechanistic: GHRH-analog-plus-secretagogue co-administration raises GH synergistically at the class level [13]. That is a statement about pharmacology, not a personal dose — and nothing on this page should be read as one.